Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Verubulin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 0.60 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 0.60 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 2/20 | 0.60 |
| ▸ | TUBA1B known ✓ | P68363 | 2/20 | 0.60 |
| ▸ | TUBA4A known ✓ | P68366 | 2/20 | 0.60 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 0.60 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 0.60 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 0.60 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 0.60 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 2/20 | 0.60 |
| ▸ | TUBA1A known ✓ | Q71U36 | 2/20 | 0.60 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 2/20 | 0.60 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 0.60 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 0.60 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 0.60 |
| ▸ | KDR | P35968 | 8/20 | 1.00 |
| ▸ | EGFR | P00533 | 6/20 | 1.00 |
| ▸ | PDGFRB | P09619 | 6/20 | 1.00 |
| ▸ | CASP1 | P29466 | 1/20 | 0.64 |
| ▸ | CASP14 | P31944 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verubulin SCHEMBL29379614 | 1.00 | KDR (1.00) | KDREGFRPDGFRBCASP1CASP14 | |
| Verubulin SCHEMBL2395194 | 0.99 | KDR (0.97) | KDREGFRPDGFRBCASP1CASP14 | |
| Verubulin SCHEMBL29505369 | 0.99 | KDR (0.97) | KDREGFRPDGFRBCASP1CASP14 | |
| Verubulin SCHEMBL3115240 | 0.89 | KDR (0.80) | KDREGFRPDGFRBCASP1CASP14 | |
| SCHEMBL3118902 | 0.86 | EGFR (0.75) | KDREGFRPDGFRBCASP1CASP14 | |
| SCHEMBL19789164 | 0.85 | EGFR (0.74) | KDREGFRPDGFRBHDAC1HDAC8 | |
| SCHEMBL3115859 | 0.85 | EGFR (0.74) | KDREGFRPDGFRBHDAC1HDAC8 | |
| SCHEMBL2259608 | 0.85 | EGFR (0.74) | KDREGFRPDGFRBHDAC1HDAC8 | |
| SCHEMBL3114791 | 0.85 | EGFR (0.74) | KDREGFRPDGFRBHDAC1HDAC8 | |
| Verubulin SCHEMBL13413700 | 0.85 | EGFR (0.74) | KDREGFRPDGFRBCASP1CASP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261739-A1 | Method of Treating Non-Small Cell Lung Cancer | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| US-20100137342-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | claimed |
| US-20100093773-A1 | METHODS OF TREATING CANCER | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20100087458-A1 | METHOD OF TREATING MELANOMA | MYRIAD PHARMACEUTICALS, INC. (US) | 2010-04-08 | — | — | US | claimed |
| US-20100087457-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | Myriad Pharmaceuticals, Inc (US) | 2010-04-08 | — | — | US | claimed |
| US-7618975-B2 | 4-arylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYRIAD PHARMACEUTICALS, INC. (US) | 2009-11-17 | — | — | US | claimed |
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2009-03-12 | — | — | US | claimed |
| WO-2009023876-A1 | METHOD OF TREATING NON-SMALL CELL LUNG CANCER | MYRIAD GENETICS, INC. (US) | 2009-02-19 | — | — | WO | claimed |
| EP-1890677-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-02-27 | — | — | EP | claimed |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-11-08 | — | — | US | claimed |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-25 | — | — | US | claimed |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INCORPORATED (US) | 2007-10-18 | — | — | US | claimed |
| WO-2006138608-A2 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-12-28 | — | — | WO | claimed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | claimed |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12378257-B2 | Metabolically stable pyrimidinyl dihydroquinoxalinones as tubulin polymerization inhibitors | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-08-05 | — | — | US | disclosed |
| EP-1660092-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Myriad Genetics, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| US-20050137213-A1 | Compounds and therapeutical use thereof | MYRIAD GENETICS, INCORPORATED (US) | 2005-06-23 | — | — | US | disclosed |
| WO-2005003100-A2 | 4-ARYLAMINO-QUINAZOLINES AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | MYRIAD GENETICS, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069350-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | TUBB4A 3378/4885TUBB 3518/4885TUBA3C 2231/4885 |
| US-12378257-B2 | Metabolically stable pyrimidinyl dihydroquinoxalinones as tubulin polymerization inhibitors | TUBB, TUBB1, TUBA1C | TUBB4A 9/4885TUBB 1/4885TUBA3C 17/4885 |
| US-20100137342-A1 | METHODS FOR TREATING VASCULAR DISRUPTION DISORDERS | VEGFA, FLT4, PDE3A | TUBB4A 127/4885TUBB 150/4885TUBA3C 349/4885 |
| US-20070249640-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | TUBB4A 3378/4885TUBB 3518/4885TUBA3C 2231/4885 |
| US-20070244113-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
| US-20070249632-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | TUBB4A 3378/4885TUBB 3518/4885TUBA3C 2231/4885 |
| US-20050137213-A1 | Compounds and therapeutical use thereof | BAD, CASP3, BAX | TUBB4A 162/4885TUBB 371/4885TUBA3C 360/4885 |
| US-20260125683-A1 | TREATMENT OF CANCERS HAVING A DRUG-RESISTANT MESENCHYMAL CELL STATE | ACTR2, RPS6KB2, EPB41L2 | TUBB4A 596/4885TUBB 1730/4885TUBA3C 2499/4885 |
| US-20100261739-A1 | Method of Treating Non-Small Cell Lung Cancer | TUBB3, NES, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | TUBB4A 4/4885TUBB 14/4885TUBA3C 30/4885 |
| US-20070259901-A1 | PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | LPXN, PNLIP, IAPP | TUBB4A 3378/4885TUBB 3518/4885TUBA3C 2231/4885 |
| US-20100087457-A1 | DOSAGES AND METHODS FOR THE TREATMENT OF CANCER | CYP3A5, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, INMT | TUBB4A 1014/4885TUBB 932/4885TUBA3C 549/4885 |
| US-20100093773-A1 | METHODS OF TREATING CANCER | TOP2A, VHL, TOP2B | TUBB4A 8/4885TUBB 20/4885TUBA3C 35/4885 |
| US-20100087458-A1 | METHOD OF TREATING MELANOMA | TYR, HNMT, PNMT | TUBB4A 10/4885TUBB 22/4885TUBA3C 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.